Date |
Title |
|
IMMUNOMEDICS EPRATUZMAB PLUS RITUXIMAB PRODUCE DURABLE COMPLETE RESPONSES IN LYMPHOMA |
|
IMMUNOMEDICS DEVELOPS NEW INTERFERON PRODUCT USING DOCK-AND-LOCK |
|
IMMUNOMEDICS REPORTS ADVANCES IN CANCER THERAPY |
|
IMMUNOMEDICS ANNOUNCES OUTCOME OF 2007 ANNUAL MEETING OF SHAREHOLDERS |
|
IMMUNOMEDICS TO PRESENT AT AMERICAN SOCIETY OF HEMATOLOGY 49th ANNUAL MEETING |
|
IMMUNOMEDICS TO PRESENT AT LAZARD CAPITAL MARKETS FOURTH ANNUAL HEALTHCARE CONFERENCE |
|
IMMUNOMEDICS
ANNOUNCES FIRST QUARTER
FISCAL 2008 RESULTS |
|
IMMUNOMEDICS TO PRESENT AT ACUMEN BIOFIN RODMAN & RENSHAW 9th ANNUAL HEALTHCARE CONFERENCE
|
|
IMMUNOMEDICS DEVELOPS TWO NEW DRUG IMMUNOCONJUGATES FOR TARGETED THERAPY OF
COLON AND LUNG CANCERS
|
|
MILATUZUMAB SHOWED PROMISING THERAPEUTIC EFFECTS ALONE AND COMBINED WITH CD20 ANTIBODY IN PRECLINICAL STUDIES
|
|
IMMUNOMEDICS TO PRESENT AT THE AACR-NCI-EORTC INTERNATIONAL CONFERENCE |
|
IMMUNOMEDICS AWARDED U.S. PATENT FOR HUMANIZED PAM4 MONOCLONAL ANTIBODY AND ITS USE IN THE DIAGNOSIS AND THERAPY OF PANCREATIC CANCER |
|
IMMUNOMEDICS ANNOUNCES FISCAL 2007 RESULTS |
|
STUDY REPORTS EPRATUZUMAB AFFECTS B-CELLS FROM PATIENTS WITH LUPUS IN A UNIQUE MANNER |
|
IMMUNOMEDICS APPOINTS EDWARD T. WOLYNIC TO BOARD OF DIRECTORS |
|
IMMUNOMEDICS SET TO JOIN RUSSELL 3000 INDEX
|
|
FRACTIONATED RADIOIMMUNOTHERAPY WITH 90Y-EPRATUZUMAB IN NON-HODGKIN’S LYMPHOMA APPEARS SAFE AND ACTIVE IN A PHASE I/II STUDY
- Results Presented at the 12th Congress of European Hematology Association (EHA) - |
|
IMMUNOMEDICS TO PRESENT AT THE SIXTH ANNUAL NEEDHAM BIOTECHNOLOGY AND MEDICAL TECHNOLOGY CONFERENCE |
|
IMMUNOMEDICS REPORTS INITIAL CLINICAL RESULTS WITH hPAM4 FOR PANCREATIC CANCER THERAPY
- Results Presented at Society of Nuclear Medicine Annual Meeting - |
|
IMMUNOMEDICS REPORTS NEW AND UPDATED CLINICAL RESULTS FROM DOSE DE-ESCALATION STUDY WITH hA20 IN LYMPHOMA PATIENTS
- Results Presented at American Society of Clinical Oncology Annual Meeting - |
|
REPEATED RADIOIMMUNOTHERAPY WITH 131I-LABETUZUMAB APPEARS SAFE AND EFFECTIVE IN COLORECTAL CANCER
WITH LIVER METASTASES
- Initial Phase II Study Results Presented at Society of Nuclear Medicine Annual Meeting - |
|
PROMISING RESULTS WITH EPRATUZUMAB AND CHEMOTHERAPY IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA
- Results from a Children’s Oncology Group (COG) Study Presented at American Society of Clinical Oncology Annual Meeting |
|
IMMUNOMEDICS TO PRESENT AT THE SOCIETY OF NUCLEAR MEDICINE 54th ANNUAL MEETING |
|
IMMUNOMEDICS TO PRESENT AT 43rd ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY |
|
IMMUNOMEDICS TO PRESENT AT ACUMEN BIOFIN RODMAN
& RENSHAW 4th ANNUAL GLOBAL HEALTHCARE CONFERENCE |
|
IMMUNOMEDICS ANNOUNCES THIRD QUARTER FISCAL
2007 RESULTS |
|
IMMUNOMEDICS COMPLETES $24 MILLION REGISTERED
DIRECT OFFERING OF COMMON STOCK |
|
IMMUNOMEDICS TO RAISE GROSS PROCEEDS OF $24
MILLION IN REGISTERED DIRECT OFFERING OF COMMON
STOCK |
|
IMMUNOMEDICS
DEVELOPS NOVEL IMMUNOTOXIN FOR THERAPY OF PROSTATE
AND LUNG CANCERS |
|
EARLY STAGE PANCREATIC CANCER EXPRESSES ANTIGEN
TARGETED BY IMMUNOMEDICS’ PAM4 ANTIBODY
-
Results Suggest PAM4 Can Be Developed For Early
Detection of Pancreatic Cancer - |
|
IMMUNOMEDICS
ANNOUNCES SECOND QUARTER FISCAL
2007 RESULTS |
|
IMMUNOMEDICS MOURNS THE LOSS OF BOARD MEMBER
RICHARD PIVIROTTO
|
